4Sc AG logo

VSC - 4Sc AG News Story

€1.41 -0.0  -0.4%

Last Trade - 14/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £61.2m
Enterprise Value £31.4m
Revenue £1.94m
Position in Universe 795th / 1053

BRIEF-4SC AG: Positive Safety Review Of Phase Ib/II Emerge Study Of Domatinostat + Avelumab In Gastrointestinal Cancer

Fri 13th December, 2019 6:31am
Dec 13 (Reuters) - 4Sc AG  VSCk.DE :
    * 4SC AG - POSITIVE SAFETY REVIEW OF PHASE IB/II EMERGE
STUDY OF
DOMATINOSTAT + AVELUMAB IN GASTROINTESTINAL CANCER
    * 4SC AG - PATIENT RECRUITMENT FOR THIRD DOSE COHORT WILL
START IN
JANUARY 2020

Source text for Eikon:  ID:nEQ5LpHmKa 
Further company coverage:  VSCk.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.